Pfizer Joins Yale Spinout in Up-to-$830M Protein Degradation Drug Collaboration

Pfizer will use Arvinas’ protein degradation technology to discover and develop new drugs for undisclosed diseases, through a collaboration that the Yale University spinout said today could generate up to $830 million-plus.The companies have signed a multi-year research collaboration and license agreement through which they have agreed to develop an unspecified number of new treatments based on Arvinas’ proprietary PROTAC® (PROteolysis TArgeting Chimeras) Platform. The novel